clarithromycin + metronidazole + proton pump inhibitor

This combination drug consists of three active ingredients—clarithromycin (a macrolide antibiotic), metronidazole (a nitroimidazole antibiotic), and a proton pump inhibitor (PPI; e.g., omeprazole, lansoprazole). It is primarily used as a first-line or alternative treatment for the eradication of Helicobacter pylori infection in patients with peptic ulcer disease. The mechanism involves: - Clarithromycin inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit. - Metronidazole causing DNA strand breakage and loss of helical structure in susceptible bacteria. - The PPI suppressing gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. The combination enhances antibacterial efficacy against H. pylori by creating a less acidic environment that increases antibiotic stability and activity[1][2][3][6]. This regimen is typically administered for 7–14 days. It is not marketed under a unique brand name but prescribed as individual components taken together.

Other names

clarithromycin triple therapy with metronidazolePPI-clarithromycin-metronidazole triple therapyclarithromycin/metronidazole/PPI regimen